12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Radium-223: Phase III started

Bayer began an open-label, Asian Phase III trial to evaluate IV radium-223 dichloride every 4 weeks for up to 6 doses in about 150 patients. The product is under Priority Review in the U.S. for the indication,...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >